These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30775293)

  • 1. Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
    Afra TP; Razmi TM; Dogra S
    Indian Dermatol Online J; 2019; 10(1):1-12. PubMed ID: 30775293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving utility of apremilast in dermatological disorders for off-label indications.
    Mehta H; Sharma A; Dogra S
    Clin Exp Dermatol; 2022 Dec; 47(12):2136-2149. PubMed ID: 35974705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.
    Gao JC; Wu AG; Contento MN; Maher JM; Cline A
    Clin Cosmet Investig Dermatol; 2022; 15():395-402. PubMed ID: 35300435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On- and Off-Label Uses of Apremilast in Dermatology.
    Plachouri KM; Georgiou S
    Acta Dermatovenerol Croat; 2020 Dec; 28(3):171-179. PubMed ID: 33422172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.
    Young M; Roebuck HL
    J Am Assoc Nurse Pract; 2016 Dec; 28(12):683-695. PubMed ID: 27869356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.
    Forchhammer S; Ghoreschi K
    Psoriasis (Auckl); 2015; 5():117-124. PubMed ID: 29387588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label studies on apremilast in dermatology: a review.
    Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
    J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T; Puig L
    Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
    De A; Das S; Dhoot D; Sarda A
    Indian J Dermatol; 2020; 65(5):396-400. PubMed ID: 33165422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast Uses and Relevance to the Military.
    Hathaway NE; Lyford WH
    Cutis; 2021 Apr; 107(4):216-220. PubMed ID: 34096849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Kang Q; Chen JS; Yang H
    Front Immunol; 2022; 13():1021537. PubMed ID: 36300119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast for the treatment of psoriasis.
    Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
    Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.